Somatostatin analogues do not preserve kidney function in ADPKD

Somatostatin analogues have been studied for years as a way to slow kidney decline in autosomal dominant polycystic kidney disease. The LIPS trial, discussed in this commentary, is described as the last randomised evaluation of the approach.

Lanreotide did not slow the primary outcome, measured GFR decline, though it suggested an effect on the creatinine-estimated GFR slope. That discrepancy is the instructive part: estimated GFR can move for reasons unrelated to true filtration — including direct tubular secretion effects of a drug — so an eGFR signal without a measured-GFR signal is a warning, not a win. The commentary concludes the trial supports the existing KDIGO recommendation against prescribing somatostatin analogues solely to preserve kidney function.

The practical message is simple: do not use lanreotide or octreotide to protect the kidney in ADPKD. Reserve somatostatin analogues for their established indications, and lean on tolvaptan and blood-pressure control for kidney protection in appropriate patients.

• Lanreotide did not slow measured GFR decline in ADPKD, the trial's primary outcome.
• An estimated-GFR signal without a measured-GFR effect should not be taken as benefit.
• KDIGO advises against somatostatin analogues solely to preserve kidney function in ADPKD.
• Rely on tolvaptan and blood-pressure control where kidney protection is the goal.

Why it matters

It closes a long-running question and warns against reading an estimated-GFR signal as kidney protection.

Don't overread it

The positive estimated-GFR slope signal is discordant with the negative measured-GFR result and should not be taken as evidence of benefit.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.